Northwest Biotherapeutics（NWBO）株式概要バイオテクノロジー企業であるノースウエスト・バイオセラピューティクス社は、がんの個別化免疫療法の開発に注力している。 詳細NWBO ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長2/6過去の実績0/6財務の健全性0/6配当金0/6報酬収益は年間193.41%増加すると予測されています 過去5年間の収益は年間2.2%増加しました。 リスク分析キャッシュランウェイが1年未満である マイナスの株主資本 意味のある収益がありません ( $2M )すべてのリスクチェックを見るNWBO Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW468,992 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA468,992 investors already sharing narrativesYour Fair ValueUS$Current PriceUS$0.1762.3% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-553m473m2016201920222025202620282031Revenue US$472.5mEarnings US$84.6mAdvancedSet Fair ValueView all narrativesNorthwest Biotherapeutics, Inc. 競合他社Anika TherapeuticsSymbol: NasdaqGS:ANIKMarket cap: US$291.5mInflaRxSymbol: NasdaqGS:IFRXMarket cap: US$309.5mEledon PharmaceuticalsSymbol: NasdaqCM:ELDNMarket cap: US$280.6mAnavex Life SciencesSymbol: NasdaqGS:AVXLMarket cap: US$300.3m価格と性能株価の高値、安値、推移の概要Northwest Biotherapeutics過去の株価現在の株価US$0.1752週高値US$0.3752週安値US$0.14ベータ-0.621ヶ月の変化-1.21%3ヶ月変化-18.85%1年変化-29.33%3年間の変化-66.32%5年間の変化-86.43%IPOからの変化-99.90%最新ニュースお知らせ • Jul 09Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of Dcvax-L for GlioblastomaNorthwest Biotherapeutics announced that the Company's Chief Technical Officer, Dr. Marnix Bosch, presented updated survival data from the Phase III trial of DCVax-L for glioblastoma (GBM) at the 2026 Annual Meeting of the British Neuro-Oncology Society (BNOS). The updated data included results of multiple different statistical analyses conducted by independent statisticians, using individual patient-level data (IPD), and demonstrated that the survival extension with DCVax-L was likely underestimated in the original analysis of the trial results. The original analysis of the DCVax-L trial results used cohort-level data to compare the results in DCVax-L patients vs. controls, as the Company only had access to cohort-level data for the controls. More recently, the Company obtained individual patient data (IPD) from several major randomized controlled trials (RCTs) in newly diagnosed glioblastoma (ndGBM), which enabled more precise matching of the DCVax-L patients and the controls. Notably, the Statistical Analysis Plan (SAP) for the DCVax-L trial had envisioned that IPD-based analyses would be undertaken when access to IPD could be obtained. Two widely recognized and rigorous statistical methods were applied by the independent statisticians for the IPD-based analyses: propensity score matching (PSM) and inverse probability weighting (IPW). The PSM analyses of two large RCTs in ndGBM found that the median survival advantage with DCVax-L treatment was 4.9 to 6.3 months, and PSM analysis of a third RCT in ndGBM found 3.4 to 3.7 months survival advantage with DCVax-L. The Hazard Ratios (HRs) ranged from 0.69 to 0.77, and the p values ranged from 0.004 to 0.027. All of these results are substantially greater than the results of the original trial analysis, which found that the median survival advantage with DCVax-L was 2.8 months based on cohort-level data. The IPW analyses, taking a different approach than the PSM analyses, delivered similar findings: median survival advantage with DCVax-L of 3.4 to 4.3 months. In addition to conducting the PSM and IPW analyses of known prognostic factors, the statisticians also conducted two forms of sensitivity analyses to check for potential unknown factors which could have confounded or biased the results: E Values and Rosenbaum's Gamma measures. The results of these sensitivity analyses demonstrated that the observed treatment effect with DCVax-L is not attributable to a hidden imbalance between the DCVax-L patients and the controls.お知らせ • Apr 01Northwest Biotherapeutics, Inc. announced delayed annual 10-K filingOn 03/31/2026, Northwest Biotherapeutics, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Nov 20Northwest Biotherapeutics, Inc., Annual General Meeting, Dec 29, 2025Northwest Biotherapeutics, Inc., Annual General Meeting, Dec 29, 2025. Location: gibson, dunn & crutcher llp, 1700 m st nw, washington, dc 20036, United Statesお知らせ • Aug 28Northwest Biotherapeutics, Inc. (OTCPK:NWBO) entered into an agreement to acquire Advent Bioservices Ltd from Toucan Holdings LLC for £1.4 million.Northwest Biotherapeutics, Inc. (OTCPK:NWBO) entered into an agreement to acquire Advent Bioservices Ltd from Toucan Holdings LLC for £1.4 million on August 27, 2025. The consideration for the acquisition will be paid in installments over two years, beginning 90 days after the acquisition agreement, with potential acceleration after regulatory approval of the Northwest's DCVax®-L product. The consideration will include a payment of £1.4 million, and payment of the net amount of accounts payable due from Northwest to Advent as of the date of the acquisition agreement for services already performed by Advent under the existing service contracts and Statements of Work (SOWs) that have been reported in Northwest’s public filings. The Net AP payable by Northwest will be the outstanding accounts payable on the agreement date reduced by certain adjustments between the parties. As part of the acquisition, Northwest will receive all of Advent's fixed assets, including extensive cryostorage and other equipment purchased by Advent over the last several years. In addition, 19 million NWBio securities that were previously issued to Advent as payment for contract services will revert back to Northwest (13.5 million shares and 5.5 million options). Certain intellectual property and other intangibles that Advent has acquired will also transfer to Northwest. At closing, Advent will become a wholly owned subsidiary of Northwest, and this is expected to enable Northwest’s operations to become fully integrated. The acquisition is also expected to enhance Northwest’s positioning for scale-up of operations, and yield important synergies and cost savings. The transaction is expected to close as soon as certain legal conditions are fulfilled.お知らせ • Aug 19Northwest Biotherapeutics, Inc. Announces the Passing of Its Senior Vice President and General Counsel, Mr. Les GoldmanNorthwest Biotherapeutics, Inc. announced the passing of its Senior Vice President and General Counsel, Mr. Les Goldman, due to a stroke. Mr. Goldman's duties are being assumed by other members of the Company's management team at this time.お知らせ • Jul 02Northwest Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $3.9 million.Northwest Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $3.9 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 17,727,273 Price\Range: $0.22最新情報をもっと見るRecent updatesお知らせ • Jul 09Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of Dcvax-L for GlioblastomaNorthwest Biotherapeutics announced that the Company's Chief Technical Officer, Dr. Marnix Bosch, presented updated survival data from the Phase III trial of DCVax-L for glioblastoma (GBM) at the 2026 Annual Meeting of the British Neuro-Oncology Society (BNOS). The updated data included results of multiple different statistical analyses conducted by independent statisticians, using individual patient-level data (IPD), and demonstrated that the survival extension with DCVax-L was likely underestimated in the original analysis of the trial results. The original analysis of the DCVax-L trial results used cohort-level data to compare the results in DCVax-L patients vs. controls, as the Company only had access to cohort-level data for the controls. More recently, the Company obtained individual patient data (IPD) from several major randomized controlled trials (RCTs) in newly diagnosed glioblastoma (ndGBM), which enabled more precise matching of the DCVax-L patients and the controls. Notably, the Statistical Analysis Plan (SAP) for the DCVax-L trial had envisioned that IPD-based analyses would be undertaken when access to IPD could be obtained. Two widely recognized and rigorous statistical methods were applied by the independent statisticians for the IPD-based analyses: propensity score matching (PSM) and inverse probability weighting (IPW). The PSM analyses of two large RCTs in ndGBM found that the median survival advantage with DCVax-L treatment was 4.9 to 6.3 months, and PSM analysis of a third RCT in ndGBM found 3.4 to 3.7 months survival advantage with DCVax-L. The Hazard Ratios (HRs) ranged from 0.69 to 0.77, and the p values ranged from 0.004 to 0.027. All of these results are substantially greater than the results of the original trial analysis, which found that the median survival advantage with DCVax-L was 2.8 months based on cohort-level data. The IPW analyses, taking a different approach than the PSM analyses, delivered similar findings: median survival advantage with DCVax-L of 3.4 to 4.3 months. In addition to conducting the PSM and IPW analyses of known prognostic factors, the statisticians also conducted two forms of sensitivity analyses to check for potential unknown factors which could have confounded or biased the results: E Values and Rosenbaum's Gamma measures. The results of these sensitivity analyses demonstrated that the observed treatment effect with DCVax-L is not attributable to a hidden imbalance between the DCVax-L patients and the controls.お知らせ • Apr 01Northwest Biotherapeutics, Inc. announced delayed annual 10-K filingOn 03/31/2026, Northwest Biotherapeutics, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Nov 20Northwest Biotherapeutics, Inc., Annual General Meeting, Dec 29, 2025Northwest Biotherapeutics, Inc., Annual General Meeting, Dec 29, 2025. Location: gibson, dunn & crutcher llp, 1700 m st nw, washington, dc 20036, United Statesお知らせ • Aug 28Northwest Biotherapeutics, Inc. (OTCPK:NWBO) entered into an agreement to acquire Advent Bioservices Ltd from Toucan Holdings LLC for £1.4 million.Northwest Biotherapeutics, Inc. (OTCPK:NWBO) entered into an agreement to acquire Advent Bioservices Ltd from Toucan Holdings LLC for £1.4 million on August 27, 2025. The consideration for the acquisition will be paid in installments over two years, beginning 90 days after the acquisition agreement, with potential acceleration after regulatory approval of the Northwest's DCVax®-L product. The consideration will include a payment of £1.4 million, and payment of the net amount of accounts payable due from Northwest to Advent as of the date of the acquisition agreement for services already performed by Advent under the existing service contracts and Statements of Work (SOWs) that have been reported in Northwest’s public filings. The Net AP payable by Northwest will be the outstanding accounts payable on the agreement date reduced by certain adjustments between the parties. As part of the acquisition, Northwest will receive all of Advent's fixed assets, including extensive cryostorage and other equipment purchased by Advent over the last several years. In addition, 19 million NWBio securities that were previously issued to Advent as payment for contract services will revert back to Northwest (13.5 million shares and 5.5 million options). Certain intellectual property and other intangibles that Advent has acquired will also transfer to Northwest. At closing, Advent will become a wholly owned subsidiary of Northwest, and this is expected to enable Northwest’s operations to become fully integrated. The acquisition is also expected to enhance Northwest’s positioning for scale-up of operations, and yield important synergies and cost savings. The transaction is expected to close as soon as certain legal conditions are fulfilled.お知らせ • Aug 19Northwest Biotherapeutics, Inc. Announces the Passing of Its Senior Vice President and General Counsel, Mr. Les GoldmanNorthwest Biotherapeutics, Inc. announced the passing of its Senior Vice President and General Counsel, Mr. Les Goldman, due to a stroke. Mr. Goldman's duties are being assumed by other members of the Company's management team at this time.お知らせ • Jul 02Northwest Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $3.9 million.Northwest Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $3.9 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 17,727,273 Price\Range: $0.22お知らせ • Jun 12Northwest Biotherapeutics Announces Upcoming Presentation on Next Generation Dendritic Cells for Enhanced Anti-Tumor TreatmentsNorthwest Biotherapeutics announced that Dr. Marnix Bosch, its Chief Technical Officer, will make a presentation on "Next Generation Dendritic Cell Treatments to Improve Anti-Tumor Responses" at the upcoming Frontiers in Cancer Immunotherapy Conference of the New York Academy of Sciences. Dr. Bosch will address certain factors and combinations of factors that may lead to supercharged dendritic cells with enhanced anti-tumor effects. The presentation will take place on June 16, at 2:50 p.m. The slides will be posted on the company's website after the presentation.お知らせ • Dec 27Northwest Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $5.504762 million.Northwest Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $5.504762 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 21,587,302 Price\Range: $0.255 Discount Per Security: $0.019125 Transaction Features: Registered Direct Offeringお知らせ • May 25Northwest Biotherapeutics, Inc., Annual General Meeting, Jun 29, 2024Northwest Biotherapeutics, Inc., Annual General Meeting, Jun 29, 2024. Location: offices of gibson, dunn & crutcher llp, 1050 connecticut avenue nw, washington, dc 20036, United Statesお知らせ • Mar 22Northwest Biotherapeutics, Inc. Appoints Pat Sarma to Its Board of DirectorsNorthwest Biotherapeutics announced that it has appointed Mr. Pat Sarma to its Board of Directors effective March 18, 2024. Mr. Sarma will initially complete the remainder of Mr. Jerry Jasinowski's term as an independent director, following Mr. Jasinowski's retirement due to health reasons as previously reported. Mr. Sarma will serve as the Chairman of the Audit Committee and member of the Compensation and Conflicts Committees. Mr. Sarma is a longtime shareholder of NWBio. In the joining the Board, he brings decades of experience as a business executive and as a venture capital investor. One of the companies he founded and built was American Megatrends Inc. (AMI), which became a major player in hardware, software and firmware components of PC-based systems. The company was known for developing the AMIBIOS firmware program for IBM-PC compatibility. The BIOS (Basic Input Output System) is the heart of PC-compatibility and all application programs access the BIOS in reading from or writing to peripheral units such as drives, keyboards, mouse. Mr. Sarma's interests in AMI were acquired, and thereafter he became a venture capital investor in the private equity markets. He was an owner for a number of years of the N.J. Devils team in the National Hockey League, and has invested in a diverse range of industries including medical and environmental companies. Mr. Sarma has been an investor in NWBio for more than a decade. Mr. Sarma received a Master's Degree in Industrial Engineering and Operations Research from Georgia Tech and a Bachelor's Degree in Mechanical Engineering from the University of Madras.お知らせ • Mar 03Northwest Biotherapeutics, Inc. announced delayed annual 10-K filingOn 03/01/2024, Northwest Biotherapeutics, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Dec 22Northwest Biotherapeutics Announces Marketing Authorization Application Has Been Submitted to the UK MHRA for DCVax-L for GlioblastomaNorthwest Biotherapeutics announced that a Marketing Authorization Application (MAA) was submitted to the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK for DCVax®?-L for glioblastoma brain cancer. The MAA seeks approval for commercialization of DCVax-L for both newly diagnosed and recurrent glioblastoma (GBM). The application also requests to be considered under the MHRA's rapid 150-day review pathway, which the agency has established for new medicines for serious unmet medical needs. GBM is the most lethal and most common form of primary brain cancer. Despite well over 400 clinical trials of a wide range of treatment agents, patient survival in newly diagnosed GBM is only 15-17 months and has not meaningful improved in 20 years; survival in recurrent GBM is only 6-8 months and has not improved in 30 years. The Company's international Phase III trial demonstrated a statistically significant and clinically meaningful extension of median survival in both newly diagnosed and recurrent GBM in patients treated with DCVax-L compared with independently selected, matched, contemporaneous, pre-specified external controls. The trial also demonstrated more than doubling of the percentage of patients alive at 5 years in newly diagnosed GBM, and more than doubling of patients alive at 3 years after tumor recurrence in recurrent GBM patients, although the numbers of patients available for comparison at late time points was small, especially in the external control populations. One of the key factors making GBM so difficult to treat is that it is an extremely heterogeneous tumor. DCVax-Direct involves essentially the same mechanism of action as DCVax-L, except that the tumor target proteins are taken up by the dendritic cells in situ in the tumor following intra-tumoral injection, rather than from tumor lysate from a surgically resected tumor tissue sample. The Company looks forward to resuming its clinical development of DCVax-Direct for a wide range of inoperable solid tumors. For the GBM MAA, the Company anticipates that the review process will be a period of intensive and extensive further work involving responding to questions and requests for further information by the regulatory authority as well as preparing for and undergoing detailed inspections of the contract research organizations (CROs) that managed the trial, the Sponsor, the Trial Master File, a number of individual trial sites selected by the regulatory from among the 94 sites that participated in the trial, the GMP facility and manufacturing information.お知らせ • Sep 13Northwest Biotherapeutics Appoints Linda Liau to its Scientific Advisory BoardNorthwest Biotherapeutics announced that Dr. Linda Liau, MD, PhD, MBA has joined the Company's Scientific Advisory Board (SAB). Dr. Liau served as the Principal Investigator of the Phase 3 trial of DCVax®-L for treatment of glioblastoma. She is Chair of the Department of Neurosurgery at UCLA, Professor and Director of the UCLA Brain Tumor Program. Dr. Liau is the former Editor-in-Chief of the Journal of Neuro-Oncology. She is the Director of the UCLA Brain Cancer SPORE (Specialized Program of Research Excellence). She is an elected member of the National Academy of Medicine. The longstanding members of the Company's Scientific Advisory Board include Dr. Samir Khleif, Dr. Jerome Galon and Dr. John Smyth, and also included Dr. Mac Cheever for many years until his passing.株主還元NWBOUS BiotechsUS 市場7D-7.1%6.3%-1.2%1Y-29.3%47.2%18.3%株主還元を見る業界別リターン: NWBO過去 1 年間で47.2 % の収益を上げたUS Biotechs業界を下回りました。リターン対市場: NWBOは、過去 1 年間で18.3 % のリターンを上げたUS市場を下回りました。価格変動Is NWBO's price volatile compared to industry and market?NWBO volatilityNWBO Average Weekly Movement8.0%Biotechs Industry Average Movement9.9%Market Average Movement7.2%10% most volatile stocks in US Market16.4%10% least volatile stocks in US Market3.1%安定した株価: NWBO 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: NWBOの 週次ボラティリティ ( 8% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト1996105Linda Powerswww.nwbio.comバイオテクノロジー企業であるノースウエスト・バイオセラピューティクス社は、がんの個別化免疫療法の開発に注力している。同社は、活性化樹状細胞を用いて患者自身の免疫系を動員し、がんを攻撃するプラットフォーム技術であるDCVaxを開発している。同社の主要製品候補はDCVax-Lで、多形性膠芽腫脳腫瘍の治療薬として第III相臨床試験を完了した。DCVax-Directも開発中で、手術不能な固形がんや様々な種類のがんを対象とした第I相臨床試験を終了している。ノースウエスト・バイオセラピューティクス社は1996年に設立され、メリーランド州ベセスダに本社を置いている。もっと見るNorthwest Biotherapeutics, Inc. 基礎のまとめNorthwest Biotherapeutics の収益と売上を時価総額と比較するとどうか。NWBO 基礎統計学時価総額US$289.28m収益（TTM）-US$38.88m売上高(TTM)US$2.17m133.1xP/Sレシオ-7.4xPER（株価収益率NWBO は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計NWBO 損益計算書（TTM）収益US$2.17m売上原価US$23.57m売上総利益-US$21.39mその他の費用US$17.49m収益-US$38.88m直近の収益報告Jun 30, 2026次回決算日該当なし一株当たり利益（EPS）-0.023グロス・マージン-984.54%純利益率-1,789.37%有利子負債／自己資本比率-149.5%NWBO の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/24 18:10終値2026/08/21 00:00収益2026/06/30年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Northwest Biotherapeutics, Inc. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Christian OrqueraFirst Berlin Equity Research GmbHBoris PeakerOppenheimer & Co. Inc.
お知らせ • Jul 09Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of Dcvax-L for GlioblastomaNorthwest Biotherapeutics announced that the Company's Chief Technical Officer, Dr. Marnix Bosch, presented updated survival data from the Phase III trial of DCVax-L for glioblastoma (GBM) at the 2026 Annual Meeting of the British Neuro-Oncology Society (BNOS). The updated data included results of multiple different statistical analyses conducted by independent statisticians, using individual patient-level data (IPD), and demonstrated that the survival extension with DCVax-L was likely underestimated in the original analysis of the trial results. The original analysis of the DCVax-L trial results used cohort-level data to compare the results in DCVax-L patients vs. controls, as the Company only had access to cohort-level data for the controls. More recently, the Company obtained individual patient data (IPD) from several major randomized controlled trials (RCTs) in newly diagnosed glioblastoma (ndGBM), which enabled more precise matching of the DCVax-L patients and the controls. Notably, the Statistical Analysis Plan (SAP) for the DCVax-L trial had envisioned that IPD-based analyses would be undertaken when access to IPD could be obtained. Two widely recognized and rigorous statistical methods were applied by the independent statisticians for the IPD-based analyses: propensity score matching (PSM) and inverse probability weighting (IPW). The PSM analyses of two large RCTs in ndGBM found that the median survival advantage with DCVax-L treatment was 4.9 to 6.3 months, and PSM analysis of a third RCT in ndGBM found 3.4 to 3.7 months survival advantage with DCVax-L. The Hazard Ratios (HRs) ranged from 0.69 to 0.77, and the p values ranged from 0.004 to 0.027. All of these results are substantially greater than the results of the original trial analysis, which found that the median survival advantage with DCVax-L was 2.8 months based on cohort-level data. The IPW analyses, taking a different approach than the PSM analyses, delivered similar findings: median survival advantage with DCVax-L of 3.4 to 4.3 months. In addition to conducting the PSM and IPW analyses of known prognostic factors, the statisticians also conducted two forms of sensitivity analyses to check for potential unknown factors which could have confounded or biased the results: E Values and Rosenbaum's Gamma measures. The results of these sensitivity analyses demonstrated that the observed treatment effect with DCVax-L is not attributable to a hidden imbalance between the DCVax-L patients and the controls.
お知らせ • Apr 01Northwest Biotherapeutics, Inc. announced delayed annual 10-K filingOn 03/31/2026, Northwest Biotherapeutics, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Nov 20Northwest Biotherapeutics, Inc., Annual General Meeting, Dec 29, 2025Northwest Biotherapeutics, Inc., Annual General Meeting, Dec 29, 2025. Location: gibson, dunn & crutcher llp, 1700 m st nw, washington, dc 20036, United States
お知らせ • Aug 28Northwest Biotherapeutics, Inc. (OTCPK:NWBO) entered into an agreement to acquire Advent Bioservices Ltd from Toucan Holdings LLC for £1.4 million.Northwest Biotherapeutics, Inc. (OTCPK:NWBO) entered into an agreement to acquire Advent Bioservices Ltd from Toucan Holdings LLC for £1.4 million on August 27, 2025. The consideration for the acquisition will be paid in installments over two years, beginning 90 days after the acquisition agreement, with potential acceleration after regulatory approval of the Northwest's DCVax®-L product. The consideration will include a payment of £1.4 million, and payment of the net amount of accounts payable due from Northwest to Advent as of the date of the acquisition agreement for services already performed by Advent under the existing service contracts and Statements of Work (SOWs) that have been reported in Northwest’s public filings. The Net AP payable by Northwest will be the outstanding accounts payable on the agreement date reduced by certain adjustments between the parties. As part of the acquisition, Northwest will receive all of Advent's fixed assets, including extensive cryostorage and other equipment purchased by Advent over the last several years. In addition, 19 million NWBio securities that were previously issued to Advent as payment for contract services will revert back to Northwest (13.5 million shares and 5.5 million options). Certain intellectual property and other intangibles that Advent has acquired will also transfer to Northwest. At closing, Advent will become a wholly owned subsidiary of Northwest, and this is expected to enable Northwest’s operations to become fully integrated. The acquisition is also expected to enhance Northwest’s positioning for scale-up of operations, and yield important synergies and cost savings. The transaction is expected to close as soon as certain legal conditions are fulfilled.
お知らせ • Aug 19Northwest Biotherapeutics, Inc. Announces the Passing of Its Senior Vice President and General Counsel, Mr. Les GoldmanNorthwest Biotherapeutics, Inc. announced the passing of its Senior Vice President and General Counsel, Mr. Les Goldman, due to a stroke. Mr. Goldman's duties are being assumed by other members of the Company's management team at this time.
お知らせ • Jul 02Northwest Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $3.9 million.Northwest Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $3.9 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 17,727,273 Price\Range: $0.22
お知らせ • Jul 09Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of Dcvax-L for GlioblastomaNorthwest Biotherapeutics announced that the Company's Chief Technical Officer, Dr. Marnix Bosch, presented updated survival data from the Phase III trial of DCVax-L for glioblastoma (GBM) at the 2026 Annual Meeting of the British Neuro-Oncology Society (BNOS). The updated data included results of multiple different statistical analyses conducted by independent statisticians, using individual patient-level data (IPD), and demonstrated that the survival extension with DCVax-L was likely underestimated in the original analysis of the trial results. The original analysis of the DCVax-L trial results used cohort-level data to compare the results in DCVax-L patients vs. controls, as the Company only had access to cohort-level data for the controls. More recently, the Company obtained individual patient data (IPD) from several major randomized controlled trials (RCTs) in newly diagnosed glioblastoma (ndGBM), which enabled more precise matching of the DCVax-L patients and the controls. Notably, the Statistical Analysis Plan (SAP) for the DCVax-L trial had envisioned that IPD-based analyses would be undertaken when access to IPD could be obtained. Two widely recognized and rigorous statistical methods were applied by the independent statisticians for the IPD-based analyses: propensity score matching (PSM) and inverse probability weighting (IPW). The PSM analyses of two large RCTs in ndGBM found that the median survival advantage with DCVax-L treatment was 4.9 to 6.3 months, and PSM analysis of a third RCT in ndGBM found 3.4 to 3.7 months survival advantage with DCVax-L. The Hazard Ratios (HRs) ranged from 0.69 to 0.77, and the p values ranged from 0.004 to 0.027. All of these results are substantially greater than the results of the original trial analysis, which found that the median survival advantage with DCVax-L was 2.8 months based on cohort-level data. The IPW analyses, taking a different approach than the PSM analyses, delivered similar findings: median survival advantage with DCVax-L of 3.4 to 4.3 months. In addition to conducting the PSM and IPW analyses of known prognostic factors, the statisticians also conducted two forms of sensitivity analyses to check for potential unknown factors which could have confounded or biased the results: E Values and Rosenbaum's Gamma measures. The results of these sensitivity analyses demonstrated that the observed treatment effect with DCVax-L is not attributable to a hidden imbalance between the DCVax-L patients and the controls.
お知らせ • Apr 01Northwest Biotherapeutics, Inc. announced delayed annual 10-K filingOn 03/31/2026, Northwest Biotherapeutics, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Nov 20Northwest Biotherapeutics, Inc., Annual General Meeting, Dec 29, 2025Northwest Biotherapeutics, Inc., Annual General Meeting, Dec 29, 2025. Location: gibson, dunn & crutcher llp, 1700 m st nw, washington, dc 20036, United States
お知らせ • Aug 28Northwest Biotherapeutics, Inc. (OTCPK:NWBO) entered into an agreement to acquire Advent Bioservices Ltd from Toucan Holdings LLC for £1.4 million.Northwest Biotherapeutics, Inc. (OTCPK:NWBO) entered into an agreement to acquire Advent Bioservices Ltd from Toucan Holdings LLC for £1.4 million on August 27, 2025. The consideration for the acquisition will be paid in installments over two years, beginning 90 days after the acquisition agreement, with potential acceleration after regulatory approval of the Northwest's DCVax®-L product. The consideration will include a payment of £1.4 million, and payment of the net amount of accounts payable due from Northwest to Advent as of the date of the acquisition agreement for services already performed by Advent under the existing service contracts and Statements of Work (SOWs) that have been reported in Northwest’s public filings. The Net AP payable by Northwest will be the outstanding accounts payable on the agreement date reduced by certain adjustments between the parties. As part of the acquisition, Northwest will receive all of Advent's fixed assets, including extensive cryostorage and other equipment purchased by Advent over the last several years. In addition, 19 million NWBio securities that were previously issued to Advent as payment for contract services will revert back to Northwest (13.5 million shares and 5.5 million options). Certain intellectual property and other intangibles that Advent has acquired will also transfer to Northwest. At closing, Advent will become a wholly owned subsidiary of Northwest, and this is expected to enable Northwest’s operations to become fully integrated. The acquisition is also expected to enhance Northwest’s positioning for scale-up of operations, and yield important synergies and cost savings. The transaction is expected to close as soon as certain legal conditions are fulfilled.
お知らせ • Aug 19Northwest Biotherapeutics, Inc. Announces the Passing of Its Senior Vice President and General Counsel, Mr. Les GoldmanNorthwest Biotherapeutics, Inc. announced the passing of its Senior Vice President and General Counsel, Mr. Les Goldman, due to a stroke. Mr. Goldman's duties are being assumed by other members of the Company's management team at this time.
お知らせ • Jul 02Northwest Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $3.9 million.Northwest Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $3.9 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 17,727,273 Price\Range: $0.22
お知らせ • Jun 12Northwest Biotherapeutics Announces Upcoming Presentation on Next Generation Dendritic Cells for Enhanced Anti-Tumor TreatmentsNorthwest Biotherapeutics announced that Dr. Marnix Bosch, its Chief Technical Officer, will make a presentation on "Next Generation Dendritic Cell Treatments to Improve Anti-Tumor Responses" at the upcoming Frontiers in Cancer Immunotherapy Conference of the New York Academy of Sciences. Dr. Bosch will address certain factors and combinations of factors that may lead to supercharged dendritic cells with enhanced anti-tumor effects. The presentation will take place on June 16, at 2:50 p.m. The slides will be posted on the company's website after the presentation.
お知らせ • Dec 27Northwest Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $5.504762 million.Northwest Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $5.504762 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 21,587,302 Price\Range: $0.255 Discount Per Security: $0.019125 Transaction Features: Registered Direct Offering
お知らせ • May 25Northwest Biotherapeutics, Inc., Annual General Meeting, Jun 29, 2024Northwest Biotherapeutics, Inc., Annual General Meeting, Jun 29, 2024. Location: offices of gibson, dunn & crutcher llp, 1050 connecticut avenue nw, washington, dc 20036, United States
お知らせ • Mar 22Northwest Biotherapeutics, Inc. Appoints Pat Sarma to Its Board of DirectorsNorthwest Biotherapeutics announced that it has appointed Mr. Pat Sarma to its Board of Directors effective March 18, 2024. Mr. Sarma will initially complete the remainder of Mr. Jerry Jasinowski's term as an independent director, following Mr. Jasinowski's retirement due to health reasons as previously reported. Mr. Sarma will serve as the Chairman of the Audit Committee and member of the Compensation and Conflicts Committees. Mr. Sarma is a longtime shareholder of NWBio. In the joining the Board, he brings decades of experience as a business executive and as a venture capital investor. One of the companies he founded and built was American Megatrends Inc. (AMI), which became a major player in hardware, software and firmware components of PC-based systems. The company was known for developing the AMIBIOS firmware program for IBM-PC compatibility. The BIOS (Basic Input Output System) is the heart of PC-compatibility and all application programs access the BIOS in reading from or writing to peripheral units such as drives, keyboards, mouse. Mr. Sarma's interests in AMI were acquired, and thereafter he became a venture capital investor in the private equity markets. He was an owner for a number of years of the N.J. Devils team in the National Hockey League, and has invested in a diverse range of industries including medical and environmental companies. Mr. Sarma has been an investor in NWBio for more than a decade. Mr. Sarma received a Master's Degree in Industrial Engineering and Operations Research from Georgia Tech and a Bachelor's Degree in Mechanical Engineering from the University of Madras.
お知らせ • Mar 03Northwest Biotherapeutics, Inc. announced delayed annual 10-K filingOn 03/01/2024, Northwest Biotherapeutics, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Dec 22Northwest Biotherapeutics Announces Marketing Authorization Application Has Been Submitted to the UK MHRA for DCVax-L for GlioblastomaNorthwest Biotherapeutics announced that a Marketing Authorization Application (MAA) was submitted to the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK for DCVax®?-L for glioblastoma brain cancer. The MAA seeks approval for commercialization of DCVax-L for both newly diagnosed and recurrent glioblastoma (GBM). The application also requests to be considered under the MHRA's rapid 150-day review pathway, which the agency has established for new medicines for serious unmet medical needs. GBM is the most lethal and most common form of primary brain cancer. Despite well over 400 clinical trials of a wide range of treatment agents, patient survival in newly diagnosed GBM is only 15-17 months and has not meaningful improved in 20 years; survival in recurrent GBM is only 6-8 months and has not improved in 30 years. The Company's international Phase III trial demonstrated a statistically significant and clinically meaningful extension of median survival in both newly diagnosed and recurrent GBM in patients treated with DCVax-L compared with independently selected, matched, contemporaneous, pre-specified external controls. The trial also demonstrated more than doubling of the percentage of patients alive at 5 years in newly diagnosed GBM, and more than doubling of patients alive at 3 years after tumor recurrence in recurrent GBM patients, although the numbers of patients available for comparison at late time points was small, especially in the external control populations. One of the key factors making GBM so difficult to treat is that it is an extremely heterogeneous tumor. DCVax-Direct involves essentially the same mechanism of action as DCVax-L, except that the tumor target proteins are taken up by the dendritic cells in situ in the tumor following intra-tumoral injection, rather than from tumor lysate from a surgically resected tumor tissue sample. The Company looks forward to resuming its clinical development of DCVax-Direct for a wide range of inoperable solid tumors. For the GBM MAA, the Company anticipates that the review process will be a period of intensive and extensive further work involving responding to questions and requests for further information by the regulatory authority as well as preparing for and undergoing detailed inspections of the contract research organizations (CROs) that managed the trial, the Sponsor, the Trial Master File, a number of individual trial sites selected by the regulatory from among the 94 sites that participated in the trial, the GMP facility and manufacturing information.
お知らせ • Sep 13Northwest Biotherapeutics Appoints Linda Liau to its Scientific Advisory BoardNorthwest Biotherapeutics announced that Dr. Linda Liau, MD, PhD, MBA has joined the Company's Scientific Advisory Board (SAB). Dr. Liau served as the Principal Investigator of the Phase 3 trial of DCVax®-L for treatment of glioblastoma. She is Chair of the Department of Neurosurgery at UCLA, Professor and Director of the UCLA Brain Tumor Program. Dr. Liau is the former Editor-in-Chief of the Journal of Neuro-Oncology. She is the Director of the UCLA Brain Cancer SPORE (Specialized Program of Research Excellence). She is an elected member of the National Academy of Medicine. The longstanding members of the Company's Scientific Advisory Board include Dr. Samir Khleif, Dr. Jerome Galon and Dr. John Smyth, and also included Dr. Mac Cheever for many years until his passing.
